Citius Oncology Enters Agreement to Sell 1,284,404 Shares at $1.09 Each

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a definitive agreement with a single healthcare-focused investor for the purchase and sale of 1,284,404 shares of its common stock at a purchase price of $1.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the company has agreed to issue to the investor unregistered warrants to purchase up to 1,284,404 shares of common stock at an exercise price of $1.09 per share, which will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval. Concurrently with the registered direct offering, in a private placement priced at-the-market under Nasdaq rules, the company entered into a definitive agreement with the investor for the purchase and sale of 15,229,358 shares of common stock and warrants to purchase up to 15,229,358 shares of the company's common stock at a purchase price of $1.09 per share and accompanying warrant. The warrants to be issued in the private placement have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.